Dr. Janeway’s prior work has uncovered genomic events underlying difficult to treat childhood solid malignancies. She has leveraged this understanding to expand treatment opportunities and improve clinical trials for children with advanced childhood solid malignancies. The research group is currently focused on better characterizing the clinical impact of genomic sequencing. A major project in the laboratory addressing this question is the iCat2/GAIN consortium study which has enrolled and sequenced over 500 patients with difficult to treat childhood solid cancers. Our group is also involved in efforts to share and aggregate both sequencing and clinical data to enable a deeper understanding of childhood cancers. We have several data generation and sharing projects aiming to better characterize the genomics of osteosarcoma and Ewing sarcoma. With these projects we hope to identify clinicogenomic factors explaining prognosis and treatment response and resistance